Targeting both IGF-1R and mTOR synergistically inhibits growth of renal cell carcinoma in vitro

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Cardillo, Thomas M ^a   Trisal, Preeti ^a   Arrojo, Roberto ^a   Goldenberg, David M ^a,b,c   Chang, Chien Hsing ^a,b  

^a IMMUNOMEDICS INC   (United States)

^b IBC Pharmaceuticals Inc   (United States)

^c GARDEN STATE CANCER CENTER   (United States)

Author keywords

1R 2b; Dock and Lock; Hex hR1; Insulin like growth factor I receptor; mTOR inhibitors; Renal cell carcinoma

Indexed keywords

1R 2B ANTIBODY; ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; HEXAVALENT HR1 ANTIBODY; HR1 ANTIBODY; MAMMALIAN TARGET OF RAPAMYCIN; SOMATOMEDIN C RECEPTOR; TEMSIROLIMUS; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER SCREENING; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; DRUG TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY CARCINOMA; PROTEIN EXPRESSION; PROTEIN FOLDING; SENSITIVITY ANALYSIS;

ANIMALS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; KIDNEY NEOPLASMS; PROTEIN KINASE INHIBITORS; RECEPTOR, IGF TYPE 1; TOR SERINE-THREONINE KINASES;

EID: 84875481104     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-170     Document Type: Article

References (37)

1. American Cancer Society Cancer Facts and Figures 2012 2012, Atlanta: American Cancer Society, American Cancer Society.
2. Fisher R, Gore M, Larkin J. Current and future systemic treatments for renal cell carcinoma. Semin Cancer Biol 2013, 23:38-45. 10.1016/j.semcancer.2012.06.004, 22705280.
3. Aschenbrenner DS. New drug approved for advanced renal cell carcinoma. Am J Nurs 2012, 112:22-23.
4. Gollob JA, Rathmell WK, Richmond TM, Marino CB, Miller EK, Grigson G, Watkins C, Gu L, Peterson BL, Wright JJ. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer. J Clin Oncol 2007, 25:3288-3295. 10.1200/JCO.2007.10.8613, 17664476.
5. Kapoor A, Figlin RA. Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma. Cancer 2009, 115:3618-3630. 10.1002/cncr.24409, 19479976.
6. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010, 28:2137-2143. 10.1200/JCO.2009.26.5561, 2860433, 20368558.
7. Motzer RJ, Rakhit A, Ginsberg M, Rittweger K, Vuky J, Yu R, Fettner S, Hooftman L. Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma. J Clin Oncol 2001, 19:1312-1319.
8. Motzer RJ, Rakhit A, Thompson J, Gurney H, Selby P, Figlin R, Negrier S, Ernst S, Siebels M, Ginsberg M, Rittweger K, Hooftman L. Phase II trial of branched peginterferon-α2a (40 kDa) for patients with advanced renal cell carcinoma. Ann Oncol 2002, 13:1799-1805. 10.1093/annonc/mdf288, 12419754.
9. O'Reilly KE, Rojo F, She Q-B, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, Baselga J, Rosen N. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006, 66:1500-1508. 10.1158/0008-5472.CAN-05-2925, 3193604, 16452206.
10. Wan X, Harkavy B, Shen N, Grohar P, Helman LJ. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 2007, 26:1932-1940. 10.1038/sj.onc.1209990, 17001314.
11. Jungwirth A, Schally AV, Pinski J, Groot K, Armatis P, Halmos G. Growth hormone-releasing hormone antagonist MZ-4-71 inhibits in vivo proliferation of Caki-I renal adenocarcinoma. Proc Natl Acad Sci USA 1997, 94:5810-5813. 10.1073/pnas.94.11.5810, 20862, 9159156.
12. Schips L, Ziegeuner R, Ratschek M, Pehak P, Rüschoff J, Langner C. Analysis of insulin-like growth factors and insulin-like growth factor I receptor expression in renal cell carcinoma. Am J Clin Pathol 2004, 122:931-937. 10.1309/G7PY0RE7T86HHQYV, 15539386.
13. Parker AS, Chebille JC, Blute ML, Igel T, Lohse CM, Cerhan JR. Pathologic T1 clear renal cell carcinoma: insulin-like growth factor-I receptor expression and disease-specific survival. Cancer 2004, 100:2577-2582. 10.1002/cncr.20322, 15197799.
14. Kidney Cancer Association http://www.kidneycancer.org/knowledge/learn/about-kidney-cancer, Kidney Cancer Association.
15. Datta K, Nambudripad R, Pal S, Zhou M, Cohen HT, Mukhopadhyay D. Inhibition of insulin-like growth factor-I-mediated cell signaling by the von Hippel-Lindau gene product in renal cancer. J Biol Chem 2000, 275:20700-20706. 10.1074/jbc.M909970199, 10748176.
16. Chang C-H, Wang Y, Trisal P, Li R, Rossi DL, Nair A, Gupta P, Losman M, Cardillo TM, Rossi EA, Goldenberg DM. Evaluation of a novel hexavalent humanized anti-IGF-1R antibody and its bivalent parental IgG in diverse cancer cell lines. PLoS One 2012, 7:e44235. 10.1371/journal.pone.0044235, 3432068, 22952934.
17. Chang CH, Rossi EA, Goldenberg DM. The dock and lock method: a novel platform technology for building multivalent, multifunctional structures of defined composition with retained bioactivity. Clin Cancer Res 2007, 13(Suppl 19):5586s-5591s.
18. Rossi EA, Goldenberg DM, Chang C-H. The Dock-and-Lock method combines recombinant engineering with site-specific covalent conjugation to generate multifunctional structures. Bioconjug Chem 2012, 23:309-323. 10.1021/bc2004999, 22168393.
19. Rossi EA, Goldenberg DM, Cardillo TM, Stein R, Chang C-H. CD20-targeted tetrameric interferon-α, a novel and potent immunocytokine for the therapy of B-cell lymphomas. Blood 2009, 114:3864-3871. 10.1182/blood-2009-06-228890, 2773491, 19710501.
20. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984, 22:27-55.
21. Reynolds CP, Maurer BJ. Evaluating response to antineoplastic drug combinations in tissue culture models. Methods Mol Med 2005, 110:173-183.
22. Kim JG, Kang MJ, Yoon Y-K, Kim H-P, Park J, Song S-H, Han S-W, Park J-W, Kang GH, Kang KW, Oh DY, Im S-A, Bang Y-J, Yi EC, Kim T-Y. Heterodimerization of glycosylated insulin-like growth factor-1 receptors and insulin receptors in cancer cells sensitive to anti-IGF1R antibody. PLoS One 2012, 7:e33322. 10.1371/journal.pone.0033322, 3306383, 22438913.
23. Zha J, O'Brien C, Savage H, Huw L-Y, Zhong F, Berry L, Lewis Phillips GD, Luis E, Cavet G, Hu X, Amler LC, Lackner MR. Molecular predictors of response to a humanized anti-insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer. Mol Cancer Ther 2009, 8:2110-2121. 10.1158/1535-7163.MCT-09-0381, 19671761.
24. Hailey J, Maxwell E, Koukouras K, Bishop WR, Pachter JA, Wang Y. Neutralizing anti-insulin-like growth factor receptor 1 antibodies inhibit receptor function and induce receptor degradation in tumor cells. Mol Cancer Res 2002, 1:1349-1353.
25. Hosono T, Tanaka T, Tanji K, Nakatani T, Kamitani T. NUBI, an interferon-inducible protein, mediates anti-proliferative actions and apoptosis in renal cell carcinoma cells through cell-cycle regulation. Br J Cancer 2010, 102:873-882. 10.1038/sj.bjc.6605574, 2833260, 20160729.
26. Bukowski R, Ernstoff MS, Gore ME, Nemunaitis JJ, Amato R, Gupta SK, Tendler CL. Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II study. J Clin Oncol 2002, 20:3841-3849. 10.1200/JCO.2002.02.051, 12228203.
27. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009, 27:3584-3590. 10.1200/JCO.2008.20.1293, 19487381.
28. Sargent ER, Gomella LG, Belldgrun A, Linehan WM, Kasid A. Epidermal growth factor receptor gene expression in normal and human kidney and renal cell carcinoma. J Urol 1989, 142:1364-1368.
29. van der Veeken J, Oliveira S, Schiffelers RM, Storm G, Roovers RC, van Bergen en Henegouwen PMP. Crosstalk between epidermal growth factor receptor- and insulin-like growth factor-1 receptor signaling: Implications for cancer therapy. Curr Cancer Drug Targets 2009, 9:748-760. 10.2174/156800909789271495, 19754359.
30. Desbois-Mouthon C, Baron A, Blivet-Van Eggeloël MJ, Fartoux L, Venot C, Bladt F, Housset C, Rosmorduc O. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for the cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma. Clin Cancer Res 2009, 15:5445-5456. 10.1158/1078-0432.CCR-08-2980, 19706799.
31. Stickle NH, Chung J, Klco JM, Hill RP, Kaelin WG, Ohh M. pVHL modification by NEDD8 is required for fibronectin matrix assembly and suppression of tumor development. Mol Cell Biology 2004, 24:3251-3261.
32. Kaelin WG. The von Hippel-Lindau tumor suppressor gene and kidney cancer. Clin Cancer Res 2004, 10(Suppl 18 Pt 2):6290s-6295s.
33. Lieubaeu-Teillet B, Rak J, Jothy S, Iliopoulos O, Kaelin W, Kerbel R. von Hippel-Lindau gene-mediated growth suppression and induction of differentiation in renal cell carcinoma cells grown as multicullular tumor spheroids. Cancer Res 1998, 58:4957-4962.
34. Kroczynska B, Kaur S, Platanias LC. Growth suppressive cytokines and the AKT/mTOR pathway. Cytokine 2009, 48:138-143. 10.1016/j.cyto.2009.07.009, 19682919.
35. Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the mTOR signaling network for cancer therapy. J Clin Oncol 2009, 27:2278-2287. 10.1200/JCO.2008.20.0766, 2738634, 19332717.
36. Zha J, Lackner MR. Targeting the insulin-like growth factor receptor-1R pathway for cancer therapy. Clin Cancer Res 2010, 16:2512-2517. 10.1158/1078-0432.CCR-09-2232, 20388853.
37. Yuen JSP, Akkaya E, Wang Y, Takiguchi M, Peak S, Sullivan M, Protheroe AS, Macaulay VM. Validation of the type 1 insulin-like growth factor receptor as a therapeutic target in renal cancer. Mol Cancer Ther 2009, 8:1448-1459. 10.1158/1535-7163.MCT-09-0101, 19509240.